Brief: Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
04/09/2024 12:33
Sept 4 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2
BESTOW
CLINICAL TRIAL ASSESSING TEGOPRUBART FOR PREVENTION OF ORGAN
REJECTION IN KIDNEY TRANSPLANT PATIENTS
* ELEDON PHARMACEUTICALS INC - ANTICIPATES REPORTING BESTOW
TOP-LINE RESULTS IN Q4 2025
Source text for Eikon: ID:nGNX4x8HFH
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial